Skip to main content
Equibles
HUMA logo

HUMA · Humacyte, Inc.

Track HUMA — free

Use HUMA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about HUMA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.60 +0.05 (+9.96%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will not have sufficient liquidity to fund our operations beyond one year from the issuance of these interim financial statements if we are unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$168.01M
Shares
277.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.60 Open$0.57 Day$0.53–0.62 52W close$0.55–2.48 Avg vol 30d7.3M Short int31.5M · 11.3% float · 6.9d Short vol80% Last earningsAug 12, 2026 DataDec 2020–Aug 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Dec 4, 2026 Est · unconfirmed · in 16 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −39%
      below
      Price vs 50-day avg −24%
      below
      RSI (14) 40
      neutral
      MACD trend Negative
      52-week position 3%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −9%
      trailing
      6-month return −47%
      trailing
      YTD return −37%
      this year
      Relative strength −61%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +1% holders QoQ · +38 funds added
      Insider flow Accumulating
      Net +$59.8K over 90 days · 0% sells
      Short interest Falling
      11.33% of float · ▼ -2.5% MoM · 6.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      167 holders — mid 3-yr range
      Squeeze score 66
      elevated · 0–100
      Fundamentals
      Strong
      EPS growth +79%
      Y/Y
      Free cash flow $-105.9M
      Balance sheet $15.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 112%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 10.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 2 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −39% Bearish
      Price vs 50-day avg
      −24% Bearish
      RSI (14)
      40 Neutral
      MACD trend
      Negative Bearish
      52-week position
      3% Bearish
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +1% holders QoQ · +38 funds added
      Insider flow Accumulating
      Net +$59.8K over 90 days · 0% sells
      Short interest Falling
      11.33% of float · ▼ -2.5% MoM · 6.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      167 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 3% Range high $2
      vs 200-day avg -39% vs 50-day avg -24%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      minimum purchase commitment of Symvess acellular tissue engineered vessels (ATEV) $1.48M March 4, 2026 —
      unit sales of Symvess 61 the year ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HUMA
      Humacyte, Inc.
      this stock
      		$168.01M -37.1% — — 11.3%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      167
      % held
      27.4%
      Net QoQ
      +14.8M sh
      Top holder
      VANGUARD CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      104
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      31.5M
      Days to cover
      6.9d
      Change
      -795.7K sh
      View
      Short Volume
      Short vol %
      80%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      32.2K
      Value
      $22.6K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      71.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$59.8K
      Buyers / Sellers
      2 / 0
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Thomas H Tuberville
      Amount
      $15.0K–$50.0K
      Traded
      May 3, 2024
      View
      Financials
      Financials
      Revenue (FY)
      $2.0M
      Net income (FY)
      $-40.8M
      EPS diluted
      $-0.26
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $41.1K
      Shares
      45.9K
      Filed
      May 18, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      HUMA -15.8% -9.1% -47.0% -7.4% -37.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -16.2% -13.5% -60.7% -11.3% -50.9%
      Key facts CIK 1818382 CUSIP 44486Q103 13F (30d) 152 filings 149 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)